Altered muscle calcium channel binding kinetics in autoimmune motoneuron disease.
While skeletal muscle is not apparently affected directly in amyotrophic lateral sclerosis (ALS), immunoglobulin G fractions purified from patients with ALS (ALS IgG) bind dihydropyridine (DHP)-sensitive L-type voltage-gated calcium channel (VGCC) antigen isolated from skeletal muscle in ELISA and Western immunoblot, and alter VGCC function in vitro. To determine whether muscle VGCC properties are altered in ALS, VGCC-enriched subsarcolemmal membrane fractions were prepared from biopsied quadriceps muscle of patients with ALS, with other neurologic diseases, or without apparent muscle disease, and tested for DHP binding with [3H]PN200-110. ALS muscle VGCCs possessed eightfold higher binding affinities for [3H]PN200-110 than did VGCCs from muscle fractions of most other patients, independent of denervation-induced increases in DHP binding site number. Similarly elevated DHP binding affinities were observed in specimens from patients with autoimmune motor neuropathies, suggesting that ALS and immune mediated motoneuron disease share skeletal muscle L-type VGCC alterations.
Smith
R G
RG
Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA.
Kimura
F
F
Harati
Y
Y
McKinley
K
K
Stefani
E
E
Appel
S H
SH
D000690:Amyotrophic Lateral Sclerosis / Q000378:metabolism*; D015220:Calcium Channels / Q000493:pharmacokinetics*; D004095:Dihydropyridines / Q000378:metabolism; D006801:Humans; D015640:Ion Channel Gating; D016472:Motor Neuron Disease / Q000378:metabolism*; D009132:Muscles / Q000378:metabolism; D009468:Neuromuscular Diseases / Q000378:metabolism
D015220:Calcium Channels; D004095:Dihydropyridines; C038806:1,4-dihydropyridine